FreeTheAI

Liquidia Settles Litigation With United Therapeutics, Removing Patent Hurdle as Shares Surge After Hours

BullishHigh impact
LQDA$26.81 −3.11%UTHR$543.40 −1.22%

Shares of Liquidia Corporation (NASDAQ:LQDA) jumped 42.48% to $38.20 in after-hours trading following the announcement of a global settlement with United Therapeutics Corporation (NASDAQ:UTHR) that resolves all pending litigation between the companies. The stock had previously closed regular market hours down 3.11% at $26.81.

The agreement comes after a U.S. District Court ruling found that United Therapeutics' patent claims covering inhaled treprostinil treatment for pulmonary hypertension associated with interstitial lung disease (PH-ILD) were valid and infringed. Under the settlement, Liquidia agreed not to appeal the decision and filed to remove the PH-ILD indication from the label for YUTREPIA. However, YUTREPIA will remain available without interruption for patients with pulmonary arterial hypertension.

To resolve the litigation and antitrust-related interests, Liquidia will make a series of payments including $60.3 million this month, a net $175 million within 30 business days, and $145.4 million in two equal installments in early 2027. Management stated that payments will be funded using cash on hand, which totaled $396.1 million at the end of September, alongside ongoing product revenue. Investors will watch how YUTREPIA's commercial performance progresses following preliminary third-quarter net product sales of $222.7 million.

Key points

  • Liquidia Corporation agreed to a global settlement with United Therapeutics Corporation to end all outstanding litigation between the two biopharmaceutical firms.
  • Liquidia will remove the PH-ILD indication from YUTREPIA while continuing to offer the medication for patients with pulmonary arterial hypertension.
  • Financial terms require Liquidia to pay a net $175 million within 30 business days, $145.4 million in 2027, and $60.3 million to resolve antitrust interests.
  • Liquidia plans to fund the settlement through ongoing YUTREPIA sales and its cash balance, which stood at $396.1 million as of September 30.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

Why did Liquidia stock rise in after-hours trading?

Liquidia stock surged after the company announced a global settlement with United Therapeutics Corporation, resolving all pending litigation between the two biotechnology firms.

What are the main terms of the Liquidia and United Therapeutics settlement?

Liquidia will remove the PH-ILD indication from YUTREPIA's label and pay United Therapeutics over $380 million across scheduled installments, funded by cash on hand and drug sales.

Will YUTREPIA remain available for pulmonary arterial hypertension patients?

Yes, Liquidia confirmed that YUTREPIA will continue to be available to patients treated for pulmonary arterial hypertension without interruption.